MEPROBAMATE by Novartis is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety. First approved in 1963.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
Meprobamate is an oral carbamate derivative anxiolytic approved in 1963 for short-term relief of anxiety disorder symptoms. It acts on multiple CNS sites including the thalamus and limbic system to produce anxiolytic effects. This is a legacy small-molecule treatment in a therapeutic area now dominated by benzodiazepines and SSRIs.
Product approaching loss of exclusivity with minimal current market data; limited team growth expected.
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on MEPROBAMATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Meprobamate offers limited career growth given its LOE-approaching status and minimal linked open positions. This role is best suited for professionals managing legacy products or transitioning to generics oversight, with low visibility and strategic priority within the company.